All In Biotech

Drug Trial Radar · NCT02085213

GOT-IT Trial: Glyceryl Trinitrate for Retained Placenta

GOT-IT Trial: A Pragmatic Group Sequential Placebo Controlled Randomised Trial to Determine the Effectiveness of Glyceryl Trinitrate for Retained Placenta.

Last checked: Nov 19, 2026Latest source record: May 21, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,107 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,107

Actual

Start

Sep 2014

Primary completion

Jul 26, 2017

Study completion Oct 5, 2017

Sponsor

Lead sponsor
University of EdinburghAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Aberdeen; NHS Lothian
First posted
Mar 12, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Single group
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A retained placenta (RP) is a complication after a normal birth, which affects nearly 11,000 women in the UK per year. This is where the placenta is not delivered spontaneously after giving birth. It is a major cause of postpartum haemorrhage (major loss of blood) which can lead to the death of the mother. The recommended treatment for RP is a surgical procedure - manual removal of placenta (MROP). This is a painful and unpleasant intervention for the women, involving additional hospital stay, and is an expensive outcome for the NHS. It is widely recognised that non-surgical management options for RP are limited and it has been recommended that research is needed into new medical treatments for RP. New effective treatments for RP would dramatically reduce the number of women requiring MROP with the operation being restricted to the small minority of women with particularly stuck placentae. The reduction in operative interventions would have cost benefits for the NHS and also for women in terms of increased satisfaction, less separation of mother and baby immediately after birth, and reduced morbidity. This study will try to prove the clinical and cost effectiveness of a known treatment for angina, Glyceryl trinitrate (GTN) used to treat RP. The investigators will compare GTN against a placebo (dummy treatment) in a randomised controlled blinded trial (GOT-IT). The GOT-IT Trial will be conducted in two phases. The first phase will involve an internal pilot study where the aim will be to test out and refine trial procedures in a small number of hospital sites. The second phase will be the main trial where recruitment will be extended to a larger number of hospitals in order to determine clinical and cost effectiveness.

Conditions

  • Placenta, Retained

Interventions

  • Glyceryl TrinitrateDrug

  • Matched PlaceboDrug

    Matched placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Need for Manual Removal of PlacentaTime frame: From time of randomisation up to 15-minutes post administration of study treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Royal Infirmary of Edinburgh

    Edinburgh, Midlothian, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.